About the Company

BioInvent (NasdaqStockholm: BINV.ST) is a biopharmaceutical company developing cancer therapeutics using its wholly-owned antibody drug discovery platform. The Company currently has 4 product candidates in clinical development with novel mechanisms of action. Lead candidate BI-1206 is an antibody targeting CD32b, which is expressed in several B-cell malignancies and is associated with resistance to rituximab, the standard of care. A Phase I/IIa study with BI-1206 in relapsed/refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) is ongoing, and initial data are expected in the first half of 2018. Secondary asset TB-403 targets the placental growth factor (PlGF) protein to inhibit neuropilin 1 (Nrp1) signaling. It is being evaluated in a Phase I/II study for medulloblastoma, a rare form of brain cancer that mostly affects children. Additional clinical candidates include THR-317 for diabetic macular edema, and BI-505 for multiple myeloma. BioInvent’s n-CoDeR/F.I.R.S.T developmental platform is validated by research collaborations with leading pharmaceutical companies that include Pfizer, Bayer, Daiichi-Sankyo, Servier, Mitsubishi Tanabe Pharma, and Xoma.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research